The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InPrecigen (PGEN) is maintaining a Buy rating following the successful commercial launch of its FDA-approved drug, Papzimeos. Management expects first-quarter revenues to exceed $18 million, driven by robust payer acceptance and strong market demand. This positive momentum has led to a revised financial outlook, with the company guiding for cash flow breakeven by 2026. Scenario analysis suggests a fair value for the stock between $6.13 and $7.01, representing a potential upside of more than 50% from current levels. The successful rollout of Papzimeos is seen as a critical catalyst for the company's long-term growth and valuation. Investors are closely monitoring the company's ability to maintain this revenue run rate as it moves toward profitability.